Miss A Strong1, medical student, University of Leeds,

1
SERUM ANTI-MULLERIAN HORMONE CONCENTRATION AS A
PREDICTOR OF OUTCOMES IN IN-VITRO FERTILISATION
IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
Miss A Strong1, medical student, University of
Leeds, Dr T Tang2, Prof. AH Balen2 Mr AJ
Rutherford2. 1. Medical student, 2. Assisted
conception unit, Leeds General Infirmary

median (range) Table 2. The clinical outcomes
of the subjects in the PCOS and non-PCOS groups.
median Table 1. The baseline characteristics
of the subjects with polycystic ovary syndrome
and those with normal ovarian morphology.
AMHanti-Müllerian hormone, BMIbody mass index,
FSHfollicle stimulating hormone, LHlutenising
hormone, PCOSpolycystic ovary syndrome,
SDstandard deviation. C.I.confidence interval,
eFSH exogenous follicle stimulating hormone,
hCG human chorionic gonadotrophin hormone
Figure 3. Receiver operator characteristic curve
for diagnosis of presence of polycystic ovary
syndrome. ROCAUC0.91.
Figure 2. Box-and-whisker plots for baseline AMH
concentration in PCOS and non-PCOS patients.

AMHanti-Müllerian hormone. ROCAUC area under
receiver operator characteristic curve,
PCOSpolycystic ovary syndrome
Figure 1. Flow
chart detailing the progression of patients
through treatment

• References
• MacDougall MJ, Tan SL, Balen A, Jacobs HS. A
  controlled study comparing patients with and
  without polycystic ovaries undergoing in-vitro
• fertilization. Hum Reprod 19938233-237.
• 2.Nardo L, Gelbaya TA, Wilkinson H, Roberts SA,
  Yates A, Pemberton PB, et al. Circulating basal
  anti-Müllerian hormone levels as predictor
• of ovarian response in women undergoing ovarian
  stimulation for in vitro fertilization. Fertil
  Steril In print 2008.
• 3. Nelson SM, Yates RW, Lyall H, Jamieson M,
  Traynor I, Gaudoin M, et al. Anti-Mullerian
  hormone-based approach to controlled ovarian
• stimulation for assisted conception. Hum Reprod
  200924(4)867-875.
• 4. La Marca A. Müllerian-inhibiting substance in
  women with polycystic ovary syndrome
  relationship with hormonal and metabolic
• characteristics. Fertil Steril 200482(4)970-972.
  
• 5.Al-Inany HG, Abou-Setta AM, Aboulghar M.
  Gonadotrophin-releasing hormone antagonists for
  assisted conception. Cochrane Database
• Syst Rev 20063CD001750.

2
A PILOT STUDY INVESTIGATES THE EFFECT OF GnRH
AGONIST ON SERUM ANTI-MULLERIAN HORMONE
CONCENTRATION IN WOMEN WITH POLYCYSTIC OVARY
SYNDROME
Miss A Strong1, Dr T Tang2, Prof. AH Balen2 Mr
AJ Rutherford2 1. Medical student, University of
Leeds 2. Assisted conception unit, Leeds General
Infirmary

Table 2. Serum AMH concentrations at baseline and
following pituitary down-regulation with
gonadotrophin releasing hormone
agonist. AMHanti-Müllerian hormone,
C.I.confidence interval, PCOSpolycystic ovary
syndrome, S.D.standard deviation.
Table 1. The baseline characteristics of
the subjects with polycystic ovary syndrome and
those with normal ovarian morphology. AMHanti-M
üllerian hormone, BMIbody mass index,
FSHfollicle stimulating hormone, LHlutenising
hormone, PCOSpolycystic ovary syndrome,
SDstandard deviation.